Cellectis (CLLS) - P/S ratio

P/S ratio as of August 2026 (TTM): 4.96

According to Cellectis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.63. At the end of 2026 the company had a P/S ratio of 4.55.

P/S ratio history for Cellectis from 2016 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	4.55	-31.05%
2025	6.60	90.49%
2024	3.47	-98.81%
2023	292	5586.57%
2022	5.14	-23.19%
2021	6.69	-61.66%
2020	17.4	-64.67%
2019	49.4	-13.25%
2018	56.9	41.84%
2017	40.1	181.3%
2016	14.3

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Regeneron Pharmaceuticals REGN	5.51	11.26%	🇺🇸 USA
uniQure QURE	187	3,665.87%	🇳🇱 Netherlands
Novavax NVAX	2.59	-47.70%	🇺🇸 USA
Flexion Therapeutics FLXN	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Cellectis (CLLS)

P/S ratio as of August 2026 (TTM): 4.96